Filtered By:
Specialty: Drugs & Pharmacology

This page shows you your search results in order of relevance. This is page number 7.

Order by Relevance | Date

Total 3220 results found since Jan 2013.

A size-shrinkable matrix metallopeptidase-2-sensitive delivery nanosystem improves the penetration of human programmed death-ligand 1 siRNA into lung-tumor spheroids
Drug Deliv. 2021 Dec;28(1):1055-1066. doi: 10.1080/10717544.2021.1931560.ABSTRACTGiven the maturation of small-interfering RNA (siRNA) techniques with nanotechnology, and because overexpression of human programmed death-ligand 1 (PD-L1) is crucial for T cell inactivation and immunosuppression of the tumor microenvironment, application of siRNA-PD-L1 has demonstrated positive progress in preclinical studies; however, the limited penetration of this compound into solid tumors remains a challenge. To decrease PD-L1 expression and increase the penetration efficacy of solid tumors, we synthesized a novel tumor-microenvironment-...
Source: Drug Delivery - June 3, 2021 Category: Drugs & Pharmacology Authors: Jiaolin Wen Neng Qiu Zejiang Zhu Peng Bai Mengshi Hu Wenyan Qi Yan Liu Ailin Wei Lijuan Chen Source Type: research

Development of Lipidoid Nanoparticles for siRNA Delivery to Neural Cells
AbstractLipidoid nanoparticles (LNPs) are the delivery platform in Onpattro, the first FDA-approved siRNA drug. LNPs are also the carriers in the Pfizer-BioNTech and Moderna COVID-19 mRNA vaccines. While these applications have demonstrated that LNPs effectively deliver nucleic acids to hepatic and muscle cells, it is unclear if LNPs could be used for delivery of siRNA to neural cells, which are notoriously challenging delivery targets. Therefore, the purpose of this study was to determine if LNPs could efficiently deliver siRNA to neurons. Because of their potential  delivery utility in either applications for the centra...
Source: The AAPS Journal - December 6, 2021 Category: Drugs & Pharmacology Source Type: research

Improved delivery of Mcl-1 and survivin siRNA combination in breast cancer cells with additive siRNA complexes
This study aimed at investigating the influence of commercial transfection reagents (Prime-Fect, Leu-Fect A, and Leu-Fect C) complexed with different siRNAs (CDC20, HSP90, Mcl-1 and Survivin) in MDA-MB-436 breast cancer cells and the impact of incorporating an anionic additive, Trans-Booster, into siRNA formulations for improving in vitro gene silencing and delivery efficiency. Gene silencing was quantitatively analyzed by real-time RT-PCR while cell proliferation and siRNA uptake were evaluated by the MTT assay and flow cytometry, respectively. Amongst the investigated siRNAs and transfection reagents, Mcl-1/Prime-Fect co...
Source: Investigational New Drugs - July 14, 2022 Category: Drugs & Pharmacology Source Type: research

Thermo-Responsive Polymer-siRNA Conjugates Enabling Artificial Control of Gene Silencing around Body Temperature
ConclusionBy fine-tuning the LCST behavior of the copolymer that was conjugated with siRNA, siRNA activity could be controlled in a thermo-responsive manner around the body temperature. This technique may offer a promising approach to induce therapeutic effects of siRNA selectively in the target site even in thein vivo conditions.
Source: Pharmaceutical Research - October 28, 2022 Category: Drugs & Pharmacology Source Type: research

Study on co-delivery of pemetrexed disodium and Bcl-2 siRNA by poly- γ-glutamic acid-modified cationic liposomes for the inhibition of NSCLC
Drug Dev Ind Pharm. 2023 Feb 20:1-18. doi: 10.1080/03639045.2023.2182125. Online ahead of print.ABSTRACTDue to the complexity of pathophysiology of non-small cell lung cancer (NSCLC) and susceptibility of single chemotherapy to drug resistance, the combination of drugs and small interfering RNA (siRNA) may produce desired therapeutic effect on NSCLC through action of multiple pathways. We designed to develop poly-γ-glutamic acid-modified cationic liposomes (γ-PGA-CL) to co-deliver pemetrexed disodium (PMX) and siRNA to treat NSCLC. Firstly, γ-PGA was modified on surface of PMX and siRNA co-loaded cationic liposomes by e...
Source: Drug Development and Industrial Pharmacy - February 21, 2023 Category: Drugs & Pharmacology Authors: Huang Xiaoyu Song Ruonan Wang Xiao Kongfang He Rumeng Shan Xie Fei Guihua Huang Source Type: research

Noninvasive delivery of siRNA and plasmid DNA into skin by fractional ablation: erbium:YAG laser versus CO2 laser.
Abstract The present study was conducted to evaluate the impacts of fractional erbium (Er):YAG and CO2 lasers on skin permeation of small interfering (si)RNA and plasmid (p)DNA vectors. In vitro skin delivery was determined with a Franz diffusion cell. In vivo absorption was investigated by observing fluorescence and confocal microscopic imaging. Fractional laser-mediated ablation of the skin resulted in significant enhancement of dextran and siRNA penetration. Respective fluxes of dextran (10 kDa) and siRNA, which had similar molecular size, with Er:YAG laser irradiation at 5 J/cm(2) were 56- and 11-fold superior...
Source: European Journal of Pharmaceutics and Biopharmaceutics - August 17, 2013 Category: Drugs & Pharmacology Authors: Lee WR, Shen SC, Chen WY, Aljuffali IA, Suen SY, Fang JY Tags: Eur J Pharm Biopharm Source Type: research

Design and Evaluation of Thioalkylated Mannose-Modified Dendrimer (G3)/α-Cyclodextrin Conjugates as Antigen-Presenting Cell-Selective siRNA Carriers
Abstract To design and evaluate the potential use of thioalkylated mannose-modified dendrimer (generation 3; G3) conjugates with α-cyclodextrin (Man-S-α-CDE (G3)) as novel antigen-presenting cell (APC)-selective siRNA carriers, we investigated the RNAi effects of siRNA complexes with Man-S-α-CDEs (G3). Man-S-α-CDE (G3, average degree of substitution of mannose (DSM) 4)/siRNA complex had the potent RNAi effects in both NR8383 cells, a rat alveolar macrophage cell line, and JAWSII cells, a mouse dendritic cell line, through adequate physicochemical properties, mannose receptor (MR)-mediated cellular uptake, and ...
Source: The AAPS Journal - September 19, 2014 Category: Drugs & Pharmacology Source Type: research

Cluster of Differentiation 44 Targeted Hyaluronic Acid Based Nanoparticles for MDR1 siRNA Delivery to Overcome Drug Resistance in Ovarian Cancer
Conclusions These findings suggest that this CD44 targeted HA-PEI/HA-PEG nanoparticle platform may be a clinicaly relevant gene delivery system for systemic siRNA-based anticancer therapeutics for the treatment of MDR cancers.
Source: Pharmaceutical Research - December 17, 2014 Category: Drugs & Pharmacology Source Type: research